Overall rank by patents
#33,039
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 3 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G01S (RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRA).
The verdict
RX holds 8 US patents across 3 technology areas, rank #33,039 of 50,000 tracked assignees.
RX Networks Inc. has been granted 8 US utility patents between 2015 and 2025, placing RX Networks Inc. at rank #33,039 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.9 claims per patent with primary concentration in G01S (RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRA). As a Foreign Corporation, RX Networks Inc. is one of the more focused assignees in the PatentsView dataset. By volume, RX sits between Roxwood Medical Inc. (8 patents, rank #33,035) and Radiant Technologies, Inc. (8 patents, rank #33,043) - the closest US assignees by grant volume. The composite Innovation Score of 26.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 5 in the 2015–2019 window, a -40% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. RX Networks Inc.'s 15.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark RX Networks Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ROXWOOD MEDICAL INC.
8 patents
RS Technologies Inc.
8 patents
RUBBER CITY BRACING COMPANY LLC
8 patents
RUSKIN COMPANY
8 patents
RYSE INC.
8 patents
Rabbit Inc.
8 patents
Racional Energy & Environment Company
8 patents
Radiant Technologies, Inc.
8 patents
RX NETWORKS INC.
8 patents
What this shows RX holds 8 patents at rank #33,039, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #33,039 in granted patent volume.
Other assignees with the most granted patents in RX's primary technology class.
RX's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
27 Top 79% higher than 21% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 12.5% |
| 2016 | 1 | 12.5% |
| 2017 | 1 | 12.5% |
| 2018 | 1 | 12.5% |
| 2019 | 1 | 12.5% |
| 2021 | 1 | 12.5% |
| 2022 | 1 | 12.5% |
| 2025 | 1 | 12.5% |
Top 3 of 3 technology areas
Overall rank by patents
#33,039
Across all tracked assignees
26.6 out of 100
How to use this portfolio
RX's 8 grants land it in the top 79% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.